Dear Colleague,
Studies show that it can cost as little as $9 million to repurpose a known compound or marketed drug, but up to twelve times as much to discover and launch a drug. These “new” economic forces are driving pharmaceutical companies to make opportunistic moves to pursue new commercial opportunities for known compounds and drugs.
As pharma revenues continue to be eroded by generic entry, the product pipelines of pharma companies are getting thinner and compounds face more safety and regulatory hurdles to approve compounds amid rising development costs. In times like these, “drug repurposing” business strategies have grown to become important ways to enhance and advance product pipelines by focusing on new markets for known compounds.
IIR is pleased to assemble the most important experts for our Drug Repurposing meeting to give you full access to the best practices and interactive discussions to help navigate through the commercial opportunities behind repurposing these new compounds.
This meeting offers detailed insights as industry thought leaders share strategies, technologies, and tools to reposition marketed or reformulated compounds.
This meeting is a great investment. Take advantage of this fantastic two day meeting to interact with repositioning and repurposing experts, network with colleagues, and develop relationships with industry professionals. Reduce cost and risk while filling pipelines with products that have a higher level of success and potentially a faster FDA approval track.
We look forward to welcoming you January 22nd in Las Vegas!
| Courtney Leonard Conference Producer Pharmaceutical & Biotech Division INSTITUTE FOR INTERNATIONAL RESEARCH | Julie Huang |
Copyright 2003-2006 IIR Holdings, Ltd. All rights Reserved